secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001193125-26-097534
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference
--------------------------------------------------------------------------------

- Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
- Cash & marketable securities $312.5M; expected runway into 2H 2028.
- Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.
- LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.
- 12-month CR data expected 2H 2026; CDRP program selected by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/0001193125-26-097534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/engn-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-097534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer